Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Janux Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 176
- +6 vs. Q3 2025
- Shares held
- 62.2M
- −2.63M (−4.1%) vs. Q3 2025
- Total value
- $860.0M
- −$725.4M (−45.8%) vs. Q3 2025
- New holders
- 44
- 69 more added
- Sold out
- 38
- 41 more reduced
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $933.4M |
| Q1 2026 | 190 | $827.8M |
| Q4 2025 | 176 | $860.0M |
| Q3 2025 | 174 | $1.59B |
| Q2 2025 | 174 | $1.51B |
| Q1 2025 | 181 | $1.81B |
| Q4 2024 | 216 | $3.43B |
| Q3 2024 | 160 | $2.07B |
| Q2 2024 | 155 | $1.87B |
| Q1 2024 | 121 | $1.59B |
| Q4 2023 | 64 | $359.5M |
| Q3 2023 | 57 | $354.0M |
| Q2 2023 | 54 | $362.1M |
| Q1 2023 | 48 | $369.5M |
| Q4 2022 | 50 | $381.3M |
| Q3 2022 | 49 | $400.3M |
| Q2 2022 | 44 | $353.0M |
| Q1 2022 | 47 | $407.1M |
| Q4 2021 | 46 | $541.6M |
| Q3 2021 | 45 | $571.2M |
| Q2 2021 | 30 | $614.5M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Janux Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −9,241−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −8,961−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −8,454−100.0% | Sold out |
| Winthrop Capital Management, LLC | 0 | $0 | 0.00% | −4,327−100.0% | Sold out |
| Avanza Fonder AB | 0 | $0 | 0.00% | −2,960−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,774−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −1,422−100.0% | Sold out |
| HighMark Wealth Management LLC | 0 | $0 | 0.00% | −265−100.0% | Sold out |
| J.Safra Asset Management Corp | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| Washington Trust Advisors, Inc. | 0 | $0 | 0.00% | −78−100.0% | Sold out |
| Rothschild Investment LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Avalon Ventures Management, LLC | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |
| Point72 Europe (London) LLP | – | – | – | – | Not filed |